LADENBURG THALM/SH SH Increases UroGen Pharma (NASDAQ:URGN) Price Target to $53.50

UroGen Pharma (NASDAQ:URGN) had its target price boosted by LADENBURG THALM/SH SH from $48.00 to $53.50 in a report released on Friday morning, Benzinga reports. LADENBURG THALM/SH SH currently has a buy rating on the stock.

A number of other brokerages have also recently commented on URGN. Oppenheimer lifted their target price on shares of UroGen Pharma from $32.00 to $40.00 and gave the stock an outperform rating in a research report on Friday. HC Wainwright increased their target price on UroGen Pharma from $54.00 to $60.00 and gave the company a buy rating in a report on Friday.

UroGen Pharma Stock Down 4.8 %

URGN opened at $18.28 on Friday. The business’s fifty day simple moving average is $13.86 and its 200 day simple moving average is $15.08. UroGen Pharma has a 52 week low of $8.69 and a 52 week high of $24.13. The stock has a market cap of $428.67 million, a PE ratio of -5.38 and a beta of 1.08.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, May 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.04). The business had revenue of $18.78 million during the quarter, compared to analyst estimates of $20.73 million. As a group, equities analysts anticipate that UroGen Pharma will post -3.6 earnings per share for the current year.

Insider Activity

In other UroGen Pharma news, insider Mark Schoenberg sold 5,153 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $13.08, for a total value of $67,401.24. Following the completion of the sale, the insider now owns 144,284 shares in the company, valued at approximately $1,887,234.72. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 11.13% of the company’s stock.

Institutional Trading of UroGen Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in URGN. RA Capital Management L.P. purchased a new position in UroGen Pharma during the third quarter valued at $20,787,000. RTW Investments LP lifted its holdings in shares of UroGen Pharma by 101.4% during the fourth quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock valued at $25,902,000 after purchasing an additional 869,344 shares in the last quarter. Silverarc Capital Management LLC purchased a new position in UroGen Pharma in the 3rd quarter worth about $7,129,000. Price T Rowe Associates Inc. MD bought a new position in UroGen Pharma during the first quarter valued at approximately $4,008,000. Finally, Superstring Capital Management LP bought a new stake in shares of UroGen Pharma in the fourth quarter worth $3,831,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.